Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Clinical trial NCT01500213 · COMPLETED

Trial details

NCT number: NCT01500213
Sponsor: Tesaro, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chemotherapy-induced Nausea and Vomiting

Start date: 2012-02-01
Primary completion: 2014-03-01
Enrollment: 555

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.